References
- Raghu G, Collard HR, Egan JJ et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med.183, 788–824 (2011).
- Collard HR, King TE Jr, Bartelson BB, Vourlekis JS, Schwarz MI, Brown KK. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.168, 538–542 (2003).
- Flaherty KR, Mumford JA, Murray S et al. Prognostic implications of physiologic and radiographic changes in idiopathic interstitial pneumonia. Am. J. Respir. Crit. Care Med.168, 543–548 (2003).
- King TE Jr, Safrin S, Starko KM et al. Analyses of efficacy end points in a controlled trial of interferon γ-1b for idiopathic pulmonary fibrosis. Chest127, 171–177 (2005).
- Zappala CJ, Latsi PI, Nicholson AG et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur. Respir. J.35, 830–836 (2010).
- du Bois RM, Weycker D, Albera C et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. DOI: 0: 201011-1790OCv1 (2011) (Epub ahead of print).
- du Bois RM, Albera C, Bradford WZ et al. Percent predicted forced vital capacity is a reliable, valid, and responsive measure of clinical status in patients with idiopathic pulmonary fibrosis (abstract). European Resp. Soc. Ann. Cong. (2010).
- Raghu G, Brown KK, Bradford WZ et al. A placebo-controlled trial of interferon γ-1b in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med.350, 125–133 (2004).
- Demedts M, Behr J, Buhl R et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med.353, 2229–2242 (2005).
- Kubo H, Nakayama K, Yanai M et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest128, 1475–1482 (2005).
- King TE Jr, Behr J, Brown KK et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.177, 75–81 (2008).
- Raghu G, Brown KK, Costabel U et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am. J. Respir. Crit. Care Med.178, 948–955 (2008).
- King TE Jr, Albera C, Bradford WZ et al. Effect of Interferon γ-1b on Survival in Patients With Idiopathic Pulmonary Fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet374, 222–228 (2009).
- Daniels CE, Lasky JA, Limper AH et al. Imatinib treatment for idiopathic pulmonary fibrosis. Randomized placebo-controlled trial results. Am. J. Respir. Crit. Care Med.181, 604–610 (2010).
- Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW; Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N. Engl. J. Med.12, 363, 620–628 (2010).
- Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377, 1760–1769 (2011).
- Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-β gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J. Pharmacol. Exp. Ther.291, 367–373 (1999).
- Azuma A, Nukiwa T, Tsuboi E et al. Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med.171, 1040–1047 (2005).
- Taniguchi H, Ebina M, Kondoh Y et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur. Respir. J.35, 821–829 (2010).
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am. J. Respir. Crit. Care Med.161, 646–664 (2000).
- Spagnolo P, Del Giovane C, Luppi F et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev.9, CD003134 (2010).
- Collard HR. Idiopathic pulmonary fibrosis and pirfenidone. Eur. Respir. J.35(4), 728–729 (2010).
- Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur. Respir. J.35, 496–504 (2010).